Gut microbiome is associated with recurrence-free survival in patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade.

Saved in:
Bibliographic Details
Title: Gut microbiome is associated with recurrence-free survival in patients with resected high-risk melanoma receiving adjuvant immune checkpoint blockade.
Authors: Usyk M; NYU Laura and Isaac Perlmutter Cancer Center, New York, NY, USA; Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA; Departments of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, NY, USA; Departments of Pediatrics (Genetics), Albert Einstein College of Medicine, Bronx, New York, NY, USA., Hayes RB; NYU Laura and Isaac Perlmutter Cancer Center, New York, NY, USA; Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA., Knight R; Departments of Pediatrics, Computer Science & Engineering, and Bioengineering, Center for Microbiome Innovation, University of California, San Diego, La Jolla, CA, USA., Gonzalez A; Departments of Pediatrics, Computer Science & Engineering, and Bioengineering, Center for Microbiome Innovation, University of California, San Diego, La Jolla, CA, USA., Li H; NYU Laura and Isaac Perlmutter Cancer Center, New York, NY, USA; Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA., Osman I; NYU Laura and Isaac Perlmutter Cancer Center, New York, NY, USA; The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, NY, USA; Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA., Weber JS; NYU Laura and Isaac Perlmutter Cancer Center, New York, NY, USA; Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA., Ahn J; NYU Laura and Isaac Perlmutter Cancer Center, New York, NY, USA; Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA. Electronic address: jiyoung.ahn@nyulangone.org.
Source: Cell [Cell] 2026 Jun 25; Vol. 189 (13), pp. 3940-3949.e14. Date of Electronic Publication: 2026 Apr 17.
Publication Type: Journal Article; Clinical Trial, Phase III
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 0413066 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4172 (Electronic) Linking ISSN: 00928674 NLM ISO Abbreviation: Cell Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1097-4172
DOI:10.1016/j.cell.2026.03.041